Hajime Isomoto, Tadashi Shimoyama, Masanori Ito, Takako Osaki, Osamu Toyoshima, Juntaro Matsuzaki, Hiroyoshi Ota, Daisuke Chinda, Mitsushige Sugimoto, Soichiro Sue, Koji Otani, Toshihiro Nishishizawa, Osamu Handa, Takahisa FURUTA, Hideki Mori, Masumi Okuda, Yuichiro Ikebuchi, Kazuhiko Inoue, Kyoko Sakai, Yuji Nadatani, Ryota Niikura, Kazuo Yashima, Tamaki Ikuse, Toshihiko Kakiuchi, Momoko Tsuda, Katsuhiro Mabe, Yasuhiro Mizuno, K Murakami, Hidekazu Suzuki
BACKGROUND: The Japanese Society for Helicobacter Research (JSHR) published the fifth edition of the guidelines for the management of Helicobacter pylori (H. pylori) infection in 2024 in Japanese language. METHODS: This edition of JSHR guidelines was first developed in accordance with the Minds Clinical Practice Guideline and Grading of Recommendations Assessment, Development, and Evaluation system. This was published after inviting public comments and external evaluations. Consensus on clinical questions (CQs) was achieved using the modified Delphi method. RESULTS: There was no change in the basic policy that all H. pylori infectious diseases are indications for eradication. Nucleic acid amplification was added to the diagnostic methods. Effects of proton-pump inhibitors (PPIs) on diagnostic tests were updated. The superiority of potassium-competitive acid blockers to PPIs in 1-week triple therapy with amoxicillin and clarithromycin has been shown. A flowchart for eradication therapy was provided for use in real-world settings. For gastric cancer prevention, eradication in earlier age is recommended. The most appropriate test and treatment strategies for adolescents are also described. Some CQs concerning gastric cancer prevention were identified, although evidence level was insufficient to make recommendations based on clinical importance. CONCLUSION: The revised guidelines facilitate the appropriate management of H. pylori infection and gastric cancer prevention.